Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly stock has advanced more than 200% over the ... commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro ... or is Lilly stock still a buy? Let's find out. So, first let's talk about the Eli Lilly story ...